ESC 2026: AstraZeneca’s oral relaxin agonist succeeds in Phase II trial
AstraZeneca’s oral relaxin agonist improved cardiac function in patients with chronic heart failure in a Phase IIb trial. In data…
Cardiovascular
-
-
ESC 2026: Head-to-head study compares inclisiran and bempedoic acid
This year at the European Society of Cardiology (ESC) Scientific Sessions, results from the Phase IV VICTORION-CHALLENGE trial provided the…
-
ESC 2026: Congress brings key readouts across the cardiovascular space
With the 2026 European Society of Cardiology (ESC) Congress in full swing, cardiologists and industry titans alike are gathering in…
-
Milestone’s etripamil nasal spray enters Phase III trial for atrial fibrillation
Milestone Pharmaceuticals has commenced a pivotal Phase III trial of its etripamil nasal spray aimed at treating atrial fibrillation with…
-
Tenax Therapeutics’ stock crashes on Phase III trial failure
Tenax Therapeutics’ stock dropped by nearly 90% after a Phase III trial of its oral therapy for pulmonary hypertension associated…
-
Placental abruption could increase risk of cardiovascular disease in women
Cardiovascular disease (CVD) is the leading cause of death globally, with the World Health Organization (WHO) estimating that 19.8 million…
-
Smartwatches could aid in monitoring heart failure exacerbations
Heart failure (HF) is a substantial global health problem that is characterised by significant mortality and poor quality of life.…
-
ACC 2026: pooled analysis supports early dapagliflozin use in acute HF care
On 30 March, at this year’s American College of Cardiology (ACC) Scientific Session, during a poster contributions session on the…
-
Theravance shuts down R&D efforts and cuts workforce by half after Phase III trial failure
Theravance Biopharma is restructuring its R&D organisation and cutting its workforce by approximately half after its rare disease blood pressure…
-
Bayer’s Factor XIa inhibitor reduces repeat stroke risk by 26% in pivotal trial
Bayer’s investigational, once-daily, oral Factor XIa inhibitor asundexian reduced the risk of recurrent ischemic stroke by 26% in a pivotal…
